Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse | Leukemia
FDA OK's New Triplet Tx for Revlimid-Refractory Multiple Myeloma | MedPage Today
Progression-free (dashed line) and overall survival (solid line) with... | Download Scientific Diagram
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial - The Lancet Oncology
Elotuzumab Plus Pomalidomide and Dexamethasone for Multiple Myeloma - YouTube
Immunotherapy: A New Approach to Treating Multiple Myeloma with Daratumumab and Elotuzumab. | Semantic Scholar
Cancers | Free Full-Text | Recent Advances in the Treatment of Patients with Multiple Myeloma
Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma | NEJM
ELOQUENT-3: A New Elotuzumab-Based Triplet Combination in Previously Treated Myeloma
Pomalidomide, Dexamethasone, & Elotuzumab Combo Trial
Multiple Myeloma with a Special Focus on Precision Medicine | Published in healthbook TIMES Oncology Hematology
Progression-free survival with elotuzumab/pomalidomide/dexamethasone... | Download Scientific Diagram
Impact of last lenalidomide dose, duration, and IMiD-free interval in patients with myeloma treated with pomalidomide/dexamethasone - ScienceDirect
Continuous Elotuzumab, Pomalidomide and Dexamethasone Maintenance Following Second Autologous Transplant for Multiple Myeloma: Results of a Prospective, Phase 2 Multicenter Trial - Transplantation and Cellular Therapy, Official Publication of the ...
Clinical Trial: For Patients Resistant to Lenalidomide, the Antibody Elotuzumab With the Newer Pomalidomide and Dex for Relapsed/Refractory Myeloma - HealthTree for Myeloma
Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study | Blood Cancer Journal
EHA Library - The official digital education library of European Hematology Association (EHA)
PDF) Elotuzumab, pomalidomide, and dexamethasone is a very well tolerated regimen associated with durable remission even in very advanced myeloma: a retrospective study from two academic centers
Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Final Overall Survival Analysis From the Randomized Phase II ELOQUENT-3 Trial | Journal of Clinical Oncology
Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial - The Lancet Haematology
Elotuzumab Plus Pomalidomide and Dexamethasone for R/R Multiple Myeloma - Cancer Therapy Advisor
Empliciti (elotuzumab) for the Treatment of Multiple Myeloma, USA
Characterization of Synergistic Selinexor Combinations of Dexamethasone, Pomalidomide, Elotuzumab and Daratumumab in Primary MM Samples Ex Vivo - ScienceDirect
Elotuzumab (Empliciti) Drug Info
Empliciti; INN-elotuzumab
